Ladenburg Thalmann Upgrades Acrivon Therapeutics to Buy, Announces $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann has upgraded Acrivon Therapeutics (NASDAQ:ACRV) from Neutral to Buy, setting a price target of $16.
September 16, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ladenburg Thalmann has upgraded Acrivon Therapeutics from Neutral to Buy, with a new price target of $16, indicating a positive outlook for the stock.
The upgrade from Neutral to Buy by Ladenburg Thalmann suggests increased confidence in Acrivon Therapeutics' future performance. The $16 price target indicates potential upside, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100